August 14, 2025 — Leads & Copy — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has appointed a commercial team to market and sell its VesCell™ therapy in Florida. The team will focus on podiatrists, vascular surgeons, and cardiologists. The goal is to treat Peripheral Artery Disease (PAD), Chronic Limb-Threatening Ischemia (CLTI), angina, ischemic cardiomyopathy, dilated cardiomyopathy, and congestive heart failure.
Croom Lawrence is the Chief Commercial Officer, Sana Farooqui is the Fractional Chief Marketing Officer, and Bob Branch is the Fractional Vice President of Digital Marketing & Media. These additions will help with the commercialization of VesCell™ in compliance with state and federal regulations. Florida’s Right-to-Try statute (SB 1768) allows physicians to offer VesCell™ to qualifying patients with informed consent.
VesCell™ aims to improve limb circulation, prevent amputation, and restore cardiac function based on published trials and studies. The company also notes early human results suggesting cognitive benefits in vascular dementia.
According to CEO Thomas Smeenk, the new team will ensure Florida practitioners are aware of the science, the law, and how VesCell™ benefits their patients.
Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix Inc.
